Back to News
Market Impact: 0.2
Immatics N.V. Announces Updated Phase 1 Data for IMA203CD8 with 51% Objective Response Rate
Source: Nasdaq
Healthcare & Biotech
Immatics N.V. announced updated Phase 1 data for IMA203CD8, a PRAME-targeted TCR T-cell therapy, across multiple advanced solid tumor types. At the August 7, 2026 data cutoff, the study included 98 heavily pretreated patients; the provided article excerpt ends before reporting the median measure or any clinical outcomes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal
- Cumberland Pharmaceuticals stock tumbles on trial results
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Best AI Stock Research Tools for Professional Investors
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More